摘要
抗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)-酪氨酸激酶抑制剂(tyrosine kinase inhibit-ors,TKIs),如拉帕替尼、吡咯替尼、奈拉替尼和图卡替尼,已成为HER2阳性乳腺癌治疗的重要选择。然而,上述药物的使用常伴随不良反应,其中腹泻是最为常见且影响显著的不良反应之一。腹泻不仅影响患者的身体健康,还会降低生存质量,甚至可能导致治疗的延迟或中断。有效的腹泻管理对于保证患者HER2-TKIs治疗的依从性和提高生存质量至关重要。目前,国内尚无针对乳腺癌抗HER2-TKIs相关腹泻的多学科管理专家共识。中国抗癌协会乳腺肿瘤整合康复专业委员会牵头,联合乳腺肿瘤、药学、消化内科、营养学及中医等多个学科的国内专家,参考国内外指南推荐、相关文献和循证医学证据,并结合国内实际情况,共同制定了《HER2阳性乳腺癌TKIs治疗相关腹泻管理的多学科专家共识》,旨在为临床医师提供一套多学科综合管理抗HER2-TKIs相关腹泻的指导建议,以提高HER2阳性乳腺癌患者的整体治疗效果和生存质量。
Human epidermal growth factor receptor 2(HER2)tyrosine kinase inhibitors(TKIs),including lapatinib,pyrotinib,neratinib,and tucatinib,have become major therapeutic options for HER2-positive breast cancer.However,the use of these agents are often associated with adverse events,of which diarrhea is one of the most common and clinically significant.Diarrhea not only negatively affects the physical health of patients but also significantly impairs their quality of life,potentially leading to treatment delays or discontinuations.Therefore,the effective management of diarrhea is crucial to ensure patient adherence to HER2-TKI therapy and improve the patients’quality of life.Cur-rently,no multidisciplinary expert consensus in China exists regarding the management of anti-HER2-TKI-related diarrhea in breast cancer.Spearheaded by the Breast Cancer Integrative Rehabilitation Professional Committee of China Anti-Cancer Association,domestic experts from multiple disciplines,including breast oncology,pharmacy,gastroenterology,nutrition,and traditional Chinese medicine,jointly de-veloped a multidisciplinary expert consensus on the management of TKI-associated diarrhea in HER2-positive breast cancer.This consensus was formulated through a comprehensive review of domestic and international guidelines,relevant literature,and evidence-based medical research while considering the clinical practice in China.This consensus aims to provide clinicians with a set of multidisciplinary,compre-hensive guidelines for managing diarrhea associated with anti-HER2-TKIs to enhance the overall treatment outcomes and quality of life of patients with HER2-positive breast cancer.
出处
《中国肿瘤临床》
北大核心
2025年第5期217-233,共17页
Chinese Journal of Clinical Oncology
关键词
HER2
阳性乳腺癌
酪氨酸激酶抑制剂
腹泻
多学科管理
专家共识
HER2-positive breast cancer
tyrosine kinase inhibitors(TKIs)
diarrhea
multidisciplinary management
expert consensus
